AI news impact · US stocks
Twist Bioscience Corp. (TWST) news impact
On 2026-11-03 Wave Radar's AI rated the news on Twist Bioscience Corp. as neutral (impact score −25%).
Genomics tools stocks pulled back with Twist falling 15%, while peer Beam Therapeutics missed Q3 estimates. Market commentary also highlighted Twist's rich valuation following a 7x run over three years.
- Direction
- Neutral
- Impact score
- −25%
- Confidence
- 75%
- Headlines read
- 5
- Date
- 2026-11-03
AI assessment
A broader genomics sector pullback and valuation scrutiny exert near-term pressure on TWST, keeping sentiment mildly negative in the absence of fresh company-specific positive catalysts.
Sector impact
Life science tools and genomics peers are seeing coordinated pullbacks as investors reassess valuations across the sector.
Headlines the AI read
- Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates Yahoo Finance/TWST · 2026-11-03
- Twist Bioscience (TWST) Stock Looks Richly Valued As Its 7x Run Continues Yahoo Finance/TWST · 2026-11-03
- 10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound Yahoo Finance/TWST · 2026-11-02
- Surging Pharma Demand and Topline Beat Drive Twist Bioscience Corporation’s (TWST) Growth Yahoo Finance/TWST · 2026-10-27
- BWX Technologies, Inc. (BWXT) Faces Share-Price Pressure Despite Strong Backlog and Higher Guidance Yahoo Finance/TWST · 2026-10-23
Rating history
One rating per trading day the stock was covered.
More on Twist Bioscience Corp.
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.